NuVasive - NUVA Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View NUVA analyst ratings or view top-rated stocks.

11 brokers have issued 1-year target prices for NuVasive's stock. Their NUVA share price forecasts range from $44.50 to $58.00. On average, they predict the company's stock price to reach $50.77 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $41.24 on January 1st, 2023. Since then, NUVA shares have decreased by 9.5% and is now trading at $37.31.
View the best growth stocks for 2023 here.

NuVasive saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 4,530,000 shares, an increase of 18.0% from the February 13th total of 3,840,000 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is presently 3.8 days.
View NuVasive's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Wednesday, February, 22nd. The medical device company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.51 by $0.08. The medical device company had revenue of $305.45 million for the quarter, compared to the consensus estimate of $311.01 million. NuVasive had a net margin of 3.36% and a trailing twelve-month return on equity of 12.45%. The business's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 EPS.

ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares S&P Small-Cap 600 Value ETF (IJS) and Vanguard S&P Small-Cap 600 Value ETF (VIOV).

NuVasive declared that its Board of Directors has initiated a share repurchase program on Tuesday, November 9th 2021, which allows the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 3.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

NuVasive updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.28 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by many different retail and institutional investors. Top institutional investors include Thrivent Financial for Lutherans (6.18%), Dimensional Fund Advisors LP (2.78%), Paradice Investment Management LLC (2.67%), Geode Capital Management LLC (1.85%), Arrowstreet Capital Limited Partnership (1.58%) and Point72 Asset Management L.P. (1.57%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends.

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $37.31.

NuVasive (NASDAQ:NUVA) has a market capitalization of $1.95 billion and generates $1.20 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.71 on an earnings per share basis.

The company employs 3,000 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.